Results 251 to 260 of about 5,979,882 (360)

Arbiter, December 17 [PDF]

open access: yes, 1979
Students of Boise State University,
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Arbiter, February 23 [PDF]

open access: yes, 2000
Students of Boise State University,
core   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Artificial Intelligence and Emotional Support: A Comparative Study of University Students with and Without Disabilities. [PDF]

open access: yesHealthcare (Basel)
Suriá-Martínez R   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy